Periodontal Disease Therapeutics Market 2021 | Global Industry Size, Share, Regional Analysis, Growth, Disease Therapeutic, Competitive Landscape and Forecast By 2026

SEATTLE, April 09, 2021, (PHARMIWEB) — Global Periodontal Disease Therapeutics Market

Periodontitis is a chronic bacterial infection caused by microbial plaque, often known as gum disease, which is colonized on tooth surface and is below the gingival margin. It involves progressive loss of the alveolar bone, which is a thickened ridge of bone that contains tooth socket over the bones that holds teeth. According to the National Institutes of Health 2017, around 20% of the global population is estimated to suffer from severe periodontitis, which is propelling the demand for diagnosis and treatment of the condition worldwide.

A sample of this report is available upon request @ https://www.coherentmarketinsights.com/insight/request-sample/2022

In periodontitis, gums are pulled away from teeth and form spaces (pockets), which are prone to get infected. If such infection is untreated, it can lead to increase periodontal pocket length and bleeding on probe, in turn leading to the alveolar bone loss and teeth loss. In order to complement a non-surgical therapy in periodontitis multiple antimicrobial options are available, such as metronidazole, chlorhexidine, minocycline, doxycycline, tetracycline, which can be locally delivered to mucosa. These drugs are used to inhibit periodontopathogenic microorganism as well as modulate the inflammatory response of tissues.

Global Periodontal Disease Therapeutics Market Dynamics

Oral care and dental hygiene are two of the major global concerns. High prevalence of periodontal disease is fuelling the demand for oral treatments. The periodontal disease is a result of various risk factors, such as ageing, smoking, poor oral hygiene, heredity, stress, and other medical conditions. The periodontal disease is majorly observed in adults. According to the Centre for Disease Control and Prevention (CDC), in 2018, the prevalence rate of periodontitis was evaluated to be over 50% in the U.S., among adults aged 30 years and above. Among those adults, 8.7% showed mild disease, 30% demonstrated moderate disease, 8.5% had severe chronic periodontitis. Disease prevalence increases with age, with 70% adults of 65 years of age and above, suffering from periodontitis. There are many environmental risk factors associated with inflammatory responses, which include smoking, diabetes mellitus, and poor health habits driving the chronic inflammatory response in periodontitis, and are beneficial for the global periodontitis disease therapeutics market development.

Moreover, advancements in treatment by using novel drugs is expected to fuel the global periodontal disease therapeutics market growth. For instance, in January 2017, ST266 by Noveome Biotherapeutics, Inc., is an expected candidate for disease treatment, which is currently in phase I clinical trials. ST266, is used to treat patients with moderate to severe periodontitis. It provide essential tools at critical stages of the healing process to restore homeostasis within the periodontal microenvironment.

Local antibiotics for the treatment of periodontal disease to present more growth opportunities in the periodontal disease therapeutics market. Increasing preference for controlled local drug delivery approaches over systemic drug delivery due to better therapeutic outcomes by achieving factors such as site specific delivery, low dose requirement, reduces side effects favors the growth of local antibiotics. Furthermore, it provide safe and effective mode of treatment and is expected to lead the market in the next few years due to various advantages. Systemic antibiotics is expected to hold dominance in global market due to factors such as product affordability, availability, and high market penetration. Growing number of preventive care for dental and gum problems and poor reimbursement policies in many economies are hindering the growth of the global periodontal disease therapeutics market.

Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2022

Global Periodontal Disease Therapeutics Market – Regional Analysis

Among regions, North America dominated the periodontal disease therapeutics market due to high awareness of periodontal disease across the region. High prevalence of periodontal disease due to desk bound or seated lifestyle, efficient reimbursements, and drug abuse. Also, increased healthcare spending has contributed to growth of market. For instance, in the U.S., according to the Centers for Medicare and Medicaid Services (CMS) spending for dental services increased by 4.6% in 2016, to US $124.4 billion, a slight acceleration from 4.4% in growth in 2015.

Asia Pacific is an emerging lucrative market for periodontal therapeutics market due to a large patient pool in the region, as well as growing healthcare infrastructure, and expenditure. Furthermore, investments in research and development for more effective therapies by prominent players in the region drives the periodontal disease therapeutics market in Asia Pacific.

Global Periodontal Disease Therapeutics Market – Key Competitors

The key players operating in the global periodontal disease therapeutics market include DenMat Holdings LLC., 3M, Valeant Pharmaceuticals International, Inc., Galderma S.A., Dexcel Pharma Ltd., Kaken Pharmaceutical Co., Ltd., and OraPharma Inc.

Market Taxonomy

By Drug Type,

• Arestin
• Atridox
• Doxycycline
• Metronidazole
• Minocycline
• Periochip
• Others

By Distribution Channel,

• Hospital Pharmacies
• Retail Pharmacies
• Online Channel

By Region,

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837